mild cognitive impairment

[ mahyld-kog-ni-tiv im-pair-muhnt ]

noun

a stage of cognitive decline, characterized by certain diminished mental abilities, as memory and concentration, but not to an extent that affects daily functioning. Abbreviation: MCI

Origin of mild cognitive impairment

First recorded in 1975–80

The company presented its final report on the pivotal studies examining aduhelm’s effectiveness—the ones behind the drug’s approval—in people with mild cognitive impairment or mild Alzheimer’s dementia.
Biogen's Controversial Alzheimer’s Drug Was Connected to a Patient Death, Just As the Company Presented Its Final Study Data | Alice Park | November 12, 2021 | Time
The companies conducted two similar studies, started several months apart, focusing on patients with mild cognitive impairment and evidence of amyloid in the brain, as confirmed by brain imaging.
Clinics Won't Provide It. Insurers Won't Cover It. So Will the First Alzheimer's Drug Make a Difference? | Tara Law | August 5, 2021 | Time
The FDA said Thursday in a statement that “it was important to clarify the intent” of the label — specifically, that any initiation of Aduhelm should occur in patients in the mild cognitive impairment or early dementia stages of Alzheimer’s.
FDA, facing intense criticism, narrows use of controversial Alzheimer’s drug to patients with early-stage disease | Laurie McGinley | July 8, 2021 | Washington Post
As a practical matter, doctors and insurers will be left to decide whether to restrict the drug to the population studied in the clinical trials — people with mild cognitive impairment and early dementia, both caused by Alzheimer’s.
Furor rages over FDA approval of controversial Alzheimer’s drug | Laurie McGinley | June 17, 2021 | Washington Post

Browse